Identifies themes and clusters of stock movements
Market TodayThemes and Stocks AnalysesThematic Stock SearchClick here for daily refresh schedule
Alzheimer Treatment Stocks$182.84
-0.80%4:00PM 11/23/2020
The global market for Alzheimer's Disease (AD) treatment will more than double in value from $4.9 billion in 2013 to reach an estimated $13.3 billion by 2023, representing a Compound Annual Growth Rate (CAGR) of 10.50%, according to research and consulting firm GlobalData.
Latest intraday update before market close @ 19:40:00 PM 11/23/2020
Summary :
Average return is down -0.6%
Median return is down -0.5%
5 out of 11 stocks are up (limited to those with intraday pricing feeds).

Aggregated price index

Aggregated price index with volume information

Summary:

  • Alzheimer Treatment stocks down 0.8% on average while median return down 0.3% in a day
  • Alzheimer Treatment stocks down 1.4% on average while median return down 1.8% in a week
  • Alzheimer Treatment stocks up 8.5% on average while median return up 7.6% in a month
  • When average return is significantly different from median return, this implies an asymmetry - composite return is driven by some outliners.

Aggregated price index is based on equal weighted constituencies returns,Aggregated volume information is based on sum of all constituencies volumes

Index Constituencies

Related ETFs (click on ticker for detail)

leak data

  • 1M winners are : Winners for past month are $DNLI 52.1%, $ACAD 27.5%, $ABBV 21.2%, $VTVT 15.7%, $CRTX 11.0%
  • 1M losers are : Losers for past month are $AVXL -2.1%, $AMGN -2.5%, $NTRP -3.7%, $SAVA -19.6%, $VYGR -24.3%
  • 1W winners are : Winners for past week are $WVE 7.1%, $CRTX 5.4%, $ACIU 5.0%, $ABBV 3.9%, $VTVT 2.1%
  • 1W losers are : Losers for past week are $AXSM -4.5%, $VYGR -4.6%, $AMGN -6.1%, $BHVN -8.0%, $SAVA -12.7%
Pick two stocks to compare:

Correlation Analysis

Index correlation analysis

Correlation for the past month is 24.8%, for the past 3 months is 29.0%

In the past month for a 5 days rolling window, the highest corrrelation is 57.4%, the lowest correlation is -2.6%, the latest correlation is 25.6%

When a correlation deviated from the normal level and goes lower or even negative, it indicates some of stocks have deviated from the normal direction of the group. The deviation could reverse if long term level of correlation was at a higher level. It creates trading opportunities and deserves study whether the deviation is idiosyncratic or systematic.

Among pairwise correlation, the highest correlation is 74.4% between AMGN and MRK

The lowest correlation is -30.3% between DNLI and VTVT

Stock news

    11/23/2020BHVN
    BioShin enrolls first patient into an Asia-Pacific regional multi-center phase III clinical trial of rimegepant (BHV-3000) for the acute treatment of migraine.

    SHANGHAI, China, Nov. 23, 2020 (GLOBE NEWSWIRE) -- BioShin Limited announced today that the first patients were enrolled in its regional multi-center study, BHV3000-310, being conducted in China and Korea. BHV3000-310 is a double-blind, randomized trial evaluating the safety and efficacy of rimegepant in the acute treatment of migraine. Karl Lintel, M.D., Chief Executive Officer of BioShin commented, “We are very pleased to have started enrollment in study BHV300-310. Rimegepant was launched in...

    11/18/2020ACIU
    Neurologist and Psychiatrist Prof. Johannes Rolf Streffer, MD Joins AC Immune SA as Chief Medical Officer

    Prof. Streffer is an established authority on neuroscience and biomarker modalities Appointment reaffirms AC Immune’s scientific leadership in neurodegenerationLAUSANNE, Switzerland, Nov. 18, 2020 (GLOBE NEWSWIRE) -- AC Immune SA (NASDAQ: ACIU), a Swiss-based, clinical-stage biopharmaceutical company with a broad pipeline focused on neurodegenerative diseases, today announced that Prof. Johannes R. Streffer, an authority on neurology and psychiatry, was hired as the Company’s Chief Medical Offi...

    11/13/2020SAVA
    Cassava Sciences Announces Pricing of $75 Million Public Offering of Common Stock

    AUSTIN, Texas, Nov. 13, 2020 (GLOBE NEWSWIRE) -- Cassava Sciences, Inc. (Nasdaq: SAVA) (the “Company” or “Cassava Sciences”), a clinical-stage biotechnology company focused on Alzheimer’s disease, today announced the pricing of its previously announced underwritten public offering. The Company is offering 9,375,000 shares of its common stock, par value $0.001 per share, at a price to the public of $8.00 per share. In connection with the offering, the Company has also granted the underwriters a 3...

    11/13/2020SAVA
    Why Cassava Sciences Stock Is Retreating Today

    The drugmaker's stock hit the skids yesterday following the announcement of an underwritten public offering. While the details of the offering have yet to be released, Cassava said that the funds would be used to fund a late-stage trial of its Alzheimer's disease drug candidate sumifilam, along with general corporate purposes. Shareholders rarely take kindly to public offerings.

    11/13/2020ACIU
    AC Immune Reports Q3 2020 Financial Results and Provides Business Update

    * Phase 1 trial completed in Lilly Morphomer™ Tau partnership program with plans to evaluate candidates in Alzheimer’s disease and NeuroOrphan indications * First-in-class TDP-43 therapeutic and diagnostic programs advance as the target’s role in a newly defined form of age-related dementia, limbic-predominant age-related TDP-43 encephalopathy (LATE), gains prominence, with a highly competitive grant awarded * All clinical and preclinical programs remain on track to meet all milestones expecte...

    11/12/2020SAVA
    Cassava Sciences Announces Proposed Public Offering of Common Stock

    AUSTIN, Texas, Nov. 12, 2020 (GLOBE NEWSWIRE) -- Cassava Sciences, Inc. (Nasdaq: SAVA) (the “Company” or “Cassava Sciences”), a clinical-stage biotechnology company focused on Alzheimer’s disease, today announced that it is commencing an underwritten public offering of shares of its common stock. The offering is subject to market and other conditions, and there can be no assurance as to whether or when the offering may be completed, or the actual size or terms of the offering. The Company expect...

    11/12/2020CRTX
    Cortexyme Announces Third Quarter 2020 Financial Results and Provides Business Update

    Cortexyme, Inc. (Nasdaq: CRTX), a clinical-stage biopharmaceutical company pioneering potential therapeutics for Alzheimer’s and other degenerative diseases, today announced financial results for the third quarter 2020 and provided an update on its business.

    11/12/2020DNLI
    Does Good News About Biogen's Alzheimer's Drug Mean Bad News for Rivals?

    Biogen's Alzheimer's disease drug, aducanumab, got positive news from the FDA last week. If the drug is approved, what does that mean for other companies with prospective Alzheimer's drug candidates?

    11/12/2020ACIU
    AC Immune to Provide Strategy and Pipeline Update During Jefferies Virtual London Healthcare Conference

    To feature discussion of the Company’s world-leading therapeutic and diagnostic candidates targeting TDP-43LAUSANNE, Switzerland, Nov. 12, 2020 (GLOBE NEWSWIRE) -- AC Immune SA (NASDAQ: ACIU), a Swiss-based, clinical-stage biopharmaceutical company with a broad pipeline focused on neurodegenerative diseases, today announced that it will participate in a fireside chat during the upcoming Jefferies Virtual London Healthcare Conference. The presentation will feature an overview of the Company’s bu...

    11/10/2020MRK
    The Daily Biotech Pulse: Lilly's COVID-19 Antibody Treatment Approved For Emergency Use, Supernus Faces Twin Regulatory Setbacks, Revance, Arena Flunk Midstage Studies

    Here's a roundup of top developments in the biotech space over the last 24 hours:Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Nov. 9) * Alcon AG (NYSE: ALC) * Aligos Therapeutics Inc (NASDAQ: ALGS) * Aptevo Therapeutics Inc (NASDAQ: APVO) (announced second complete remission in a patient in Cohort 6 of a Phase 1 study of AVO436 in acute myeloid leukemia and myelodysplastic syndrome patients) * Bio-Rad Laboratories, Inc. Class A Common Stock (NYSE: BIO) * BIO-TECHNE Corp (NASDAQ: ...